GlassScriptPhysician profile
Jay Kenneth Mattheis
NPI 1154311058
$176,322.81
in general payments reported to CMS, 2019-2025
21 companies · $621 in 2025
The $621 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121K · 2020: $43K · 2021: $11K · 2023: $442 · 2024: $538 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,600.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $44,659.60 | 2019-2021 | |
| Shire North American Group INC | $41,587.40 | 2019 | |
| Sun Pharmaceutical Industries INC. | $24,870.14 | 2019-2021 | |
| Biotissue Holdings INC. | $23,283.16 | 2019-2024 | |
| Aerie Pharmaceuticals, INC. | $20,258.28 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $10,195.24 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $9,476.00 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $579.46 | 2023-2024 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $342.78 | 2021-2025 | Tryptyr, Hydrus Microstent, Rocklatan |
| Allergan, INC. | $248.80 | 2019-2021 | |
| Sight Sciences, INC. | $193.49 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Eyevance Pharmaceuticals LLC | $150.96 | 2021 | |
| Ani Pharmaceuticals, INC. | $122.23 | 2024-2025 | Purified Cortrophin Gel, Yutiq |
| Johnson & Johnson Surgical Vision, INC. | $75.84 | 2024-2025 | Tecnis Simplicity |
| Abbvie INC. | $58.50 | 2024-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $53.97 | 2024-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $52.06 | 2023-2024 | Eylea, Eylea Hd |
| Akorn Operating Company LLC | $42.04 | 2021 | |
| Dompe US, INC. | $29.91 | 2024 | Oxervate |
| Staar Surgical Company | $25.24 | 2019 | |
| Glaukos Corporation | $17.71 | 2024 | Idose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Mattheis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.